Alhemo access in India: the CDSCO Rule 36 named-patient pathway
How families in India legally obtain Alhemo (concizumab-mtci) for hemophilia A or B prophylaxis (with or without inhibitors) from US-source supply through CDSCO personal importation, with validated 2 to 8 degree Celsius cold-chain and daily subcutaneous dosing logistics built into the case plan.
Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.
Ask about Alhemo in India
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
Quick orientation
Alhemo (concizumab-mtci) is a humanized IgG4 monoclonal antibody from Novo Nordisk that targets tissue factor pathway inhibitor (TFPI), restoring factor Xa generation in patients whose intrinsic coagulation cascade is broken by an absence of factor VIII or factor IX activity. It is supplied as a single-patient prefilled pen for once-daily subcutaneous injection. The US Food and Drug Administration first approved Alhemo on 20 December 2024 for routine prophylaxis in adult and pediatric patients 12 years of age and older with hemophilia A or B with inhibitors, and the label has since expanded to include hemophilia A or B without inhibitors. Alhemo is not registered with the CDSCO as of this review. Indian patients with the relevant hematology indication reach Alhemo through the Central Drugs Standard Control Organization (CDSCO) personal importation framework under Rule 36 of the Drugs and Cosmetics Rules 1945, with the Form 12A application and Form 12B permit issued by the office of the Drugs Controller General of India (DCGI). Reserve Meds coordinates the supply through a US-licensed pharmaceutical wholesale partner, validated 2 to 8 degree Celsius cold-chain logistics with temperature monitoring through to handoff, and the documentation kit your treating hematologist needs to file.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Reserved for you.
How Alhemo reaches patients in India
Alhemo (concizumab-mtci, a humanised IgG4 monoclonal antibody targeting tissue factor pathway inhibitor, FDA-approved 20 December 2024 for routine prophylaxis in patients 12 years and older with haemophilia A or B with FVIII or FIX inhibitors, label at accessdata.fda.gov) is not listed on the Central Drugs Standard Control Organization SUGAM approved-product search at cdscoonline.gov.in as of 2026-06-01. Patients obtain Alhemo under the Permission to Import Small Quantities of New Drug for Personal Use, the statutory Form 12-B Permit applied for via Form 12-A under Rules 36 and 36A of the Drugs and Cosmetics Rules 1945 read with the New Drugs and Clinical Trials Rules 2019, pathway page at cdsco.gov.in. Applications run through the SUGAM portal at cdscoonline.gov.in/CDSCO/Drugs_Personal. We give you a written timeline estimate for your case before you commit. Where a hospital files on a named patient's behalf, the Import Licence for Personal Use in CT Form-16 under the Second Schedule and Table-1 of the New Drugs and Clinical Trials Rules 2019 is the institutional channel, rules text at cdsco.gov.in/Acts-and-rules/New-Drugs. The prescription must come from a registered medical practitioner with a current National Medical Commission registration number, paired with a treating physician's case summary and a pro-forma invoice. Quantity per permit is read conventionally as up to a three-month supply.
Where Alhemo is dispensed in India
Alhemo is a refrigerated 2 to 8 degree Celsius prefilled pen administered as a once-daily subcutaneous injection. Dispensing routes through haemophilia treatment centres and tertiary haematology services with refrigerated-biologic handling, family pen-training, and inhibitor-monitoring infrastructure. State Hemophilia Society chapters maintain bleed and inhibitor registries that feed directly into the clinical justification letter. The dispensing facility must hold a drug licence covering refrigerated biologics.
What Alhemo costs in India
Medicine price: quote on request. You get a written quote for your case before you commit. Dosing is weight-based at a 1 mg/kg loading dose on Day 1 followed by 0.2 mg/kg subcutaneous once daily from Day 2, with a plasma-concentration check at approximately 4 weeks driving titration to 0.25 mg/kg or 0.15 mg/kg per label thresholds. For a 70 kg adult, the daily 0.2 mg/kg maintenance dose is 14 mg, translating to roughly 420 mg per month at steady state. Goods and Services Tax on life-saving medicines sits at 5 percent.
Funding and access barriers for Alhemo in India
Indefinite prophylactic dosing of a 2 to 8 degree Celsius biologic on a daily subcutaneous cadence does not fit the one-time-treatment ceiling structure naturally. State haemophilia programmes vary; Karnataka, Maharashtra, Tamil Nadu, and Kerala have historically provided factor concentrate through state Hemophilia Society partnerships but coverage of unregistered subcutaneous prophylactic biologics is not the norm. Medicine price: quote on request. You get a written quote for your case before you commit. private health insurers assess unregistered named-patient imports case by case and most retail policies sub-limit or exclude unregistered drugs. The dominant funding pattern for an Alhemo case is family self-pay, often supplemented by diaspora remittance, crowdfunding through Ketto, Milaap, and ImpactGuru, and the Novo Nordisk Haemophilia Foundation patient-access initiatives where applicable. Customs handling for refrigerated biologics is the operational complication beyond funding; CDSCO documentation completeness governs the speed of clearance at Delhi, Mumbai, Bengaluru, Chennai, and Hyderabad airports.
Recent regulatory and access news for Alhemo
The CDSCO Notifications feed at cdsco.gov.in/Notifications has not posted a concizumab-specific notification over the last 12 months as of 2026-06-01. The Ministry of Health and Family Welfare continues quarterly Health Minister's Committee updates on the NPRD 2021 Centres of Excellence and disease coverage. On the manufacturer side, Novo Nordisk has continued regional rollout of concizumab through 2025 and 2026 quarterly disclosures with EMA approval published in the EPAR at ema.europa.eu Alhemo EPAR; the US label expansion in 2025 broadened the indication beyond inhibitor cohorts. India-specific CDSCO filings have not appeared on the SUGAM approved-product search at cdscoonline.gov.in as of the snapshot date.
Where Reserve Meds fits in Alhemo cases
Reserve Meds is a US-based digital health company. We do not replace your hematologist, do not replace CDSCO or the DCGI, and do not replace the dispensing hospital pharmacy or the licensed specialty importer. What we do is orchestrate the supply through a US-licensed pharmaceutical wholesale partner under DSCSA serialization with full pedigree, validated 2 to 8 degree Celsius cold-chain logistics with temperature monitoring through to handoff, and the documentation kit your treating hematologist needs for the Form 12A filing. Standard NPP coordination applies with particular attention to the once-daily subcutaneous cadence (which leaves no buffer for prolonged customs delays), the thrombosis risk surveillance the prescribing hematologist holds, the 4-week plasma-concentration milestone that drives the dose-titration decision, and family training on the prefilled pen and injection-site rotation. A single point of contact carries the case from intake through indefinite chronic prophylaxis dosing.
Next step
If an Indian patient with hemophilia A or B has a treating hematologist considering Alhemo prophylaxis, start your case at the portal. We will respond within one business day with a documentation kit for your hematologist and a written quote scaled to the patient's current weight.
Reserved for you.
This guide is informational, not medical or legal advice. The named-patient framework requires a licensed Indian physician's clinical judgment; Reserve Meds is the coordinator, not the prescriber.